JP2011503199A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503199A5
JP2011503199A5 JP2010534194A JP2010534194A JP2011503199A5 JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5 JP 2010534194 A JP2010534194 A JP 2010534194A JP 2010534194 A JP2010534194 A JP 2010534194A JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5
Authority
JP
Japan
Prior art keywords
heterocyclic
condensed
nhr
benzene
cycloalkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010534194A
Other languages
English (en)
Japanese (ja)
Other versions
JP5450434B2 (ja
JP2011503199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083478 external-priority patent/WO2009064938A1/en
Publication of JP2011503199A publication Critical patent/JP2011503199A/ja
Publication of JP2011503199A5 publication Critical patent/JP2011503199A5/ja
Application granted granted Critical
Publication of JP5450434B2 publication Critical patent/JP5450434B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010534194A 2007-11-16 2008-11-14 関節炎の治療方法 Expired - Fee Related JP5450434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
US60/988,479 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013232754A Division JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Publications (3)

Publication Number Publication Date
JP2011503199A JP2011503199A (ja) 2011-01-27
JP2011503199A5 true JP2011503199A5 (enExample) 2012-01-05
JP5450434B2 JP5450434B2 (ja) 2014-03-26

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534194A Expired - Fee Related JP5450434B2 (ja) 2007-11-16 2008-11-14 関節炎の治療方法
JP2013232754A Expired - Fee Related JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013232754A Expired - Fee Related JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Country Status (14)

Country Link
US (2) US20090176785A1 (enExample)
EP (1) EP2231159A1 (enExample)
JP (2) JP5450434B2 (enExample)
KR (1) KR101585848B1 (enExample)
CN (1) CN101969951B (enExample)
AU (1) AU2008322595B2 (enExample)
CA (1) CA2705294C (enExample)
DO (1) DOP2013000169A (enExample)
IL (2) IL205501A (enExample)
MX (1) MX2010005395A (enExample)
NZ (2) NZ585085A (enExample)
RU (2) RU2472509C2 (enExample)
WO (1) WO2009064938A1 (enExample)
ZA (1) ZA201003434B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE026241T2 (en) 2010-03-25 2016-06-28 Abbvie Inc Cell death triggers for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
SG10201801794WA (en) 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
MY165884A (en) 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
KR101923364B1 (ko) 2010-11-23 2018-11-30 애브비 인코포레이티드 아폽토시스­유도제의 염 및 결정형
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG11202001553UA (en) 2017-08-23 2020-03-30 Newave Pharmaceutical Inc Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021092030A1 (en) 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
EP4110298A1 (en) 2020-02-24 2023-01-04 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a bcl2 inhibitor
US20240166646A1 (en) 2020-12-22 2024-05-23 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
ES2138366T3 (es) * 1995-10-10 2000-01-01 Pfizer Indol carbamatos como antagonistas de leucotrienos.
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
PT1660491E (pt) * 2003-07-28 2008-10-10 Janssen Pharmaceutica Nv Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
RS20060143A (sr) * 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
EP2757099B1 (en) * 2005-05-12 2017-08-23 AbbVie Bahamas Limited Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Similar Documents

Publication Publication Date Title
RU2012143212A (ru) Способ лечения артрита
RU2011134634A (ru) Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP5517935B2 (ja) 細胞壊死阻害剤としてのインドール及びインダゾール化合物
AU2016256728B2 (en) Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
JP2016534134A5 (enExample)
PE20210402A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
JP2014511869A5 (enExample)
RU2356893C2 (ru) Ингибиторы фосфодиэстеразы 4
JP2014501732A5 (enExample)
JP2005526723A5 (enExample)
JP2016540742A5 (enExample)
RU2011134631A (ru) Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2018526413A5 (enExample)
JP2016530322A5 (enExample)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
RU2012107101A (ru) Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы
JP2013532709A5 (enExample)
JP2011518807A5 (enExample)
JP2017503765A5 (enExample)
JP2018503661A5 (enExample)
JP2016534984A5 (enExample)
EA200700756A1 (ru) Пиримидоны
JP2016523276A5 (enExample)
RU2016102149A (ru) Применение сигма-лигандов для предотвращения и лечения боли, связанной с интерстициальным циститом/синдромом раздраженного мочевого пузыря (иц/срмп)
JP2018515489A5 (enExample)